HTT EXON1

# Research Brief: HTT Exon 1 Q23 Variant ## Pathogenic Mechanisms The HTT exon 1 Q23 variant represents a polyglutamine expansion within the critical first exon of the huntingtin gene, which encodes key regulatory domains including the N17 region. Research has identified that the N17 domain and specific residues within exon 1 play crucial roles in controlling mutant huntingtin localization, aggregation propensity, and cellular toxicity. The expanded polyglutamine tract in this variant disrupts normal huntingtin function, which includes essential molecular interactions with beta-tubulin binding, dynactin binding, and dynein intermediate chain binding. These disruptions affect critical biological processes including apoptotic pathways, central nervous system development, and establishment of mitotic spindle orientation. The protein's known interactors—ZDHHC17, UBAC1, RNF20, UBE2K, and ARFGAP3—suggest involvement in post-translational modification, protein degradation, and membrane trafficking pathways that may be compromised by the Q23 expansion. The pathogenic mechanism appears to involve both loss of normal huntingtin function and gain of toxic properties through aberrant protein aggregation. ## Clinical Significance The Q23 expansion in HTT exon 1 represents a critical threshold in polyglutamine tract length that influences disease manifestation. While the specific pathogenicity classification and population frequency data require further characterization, exon 1 variants are particularly significant as this region is both necessary and sufficient for aggregate formation and toxicity in cellular and animal models. The functional consequences extend beyond simple protein misfolding to affect multiple cellular processes including cytoskeletal organization, intracellular transport, and programmed cell death. The variant's impact on central nervous system development suggests potential neurodevelopmental consequences in addition to the neurodegenerative phenotype typically associated with huntingtin pathology. ## Therapeutic Landscape Computational analysis has identified a significant aggregation hotspot at residues 1497-1501 (aggregation score: 0.83), which has led to the development of candidate peptide CP-HTT-001 specifically targeting this region. This represents a rational therapeutic strategy to prevent or disrupt pathogenic protein aggregation at a key nucleation site. The identification of this hotspot downstream of exon 1 suggests that the Q23 expansion may influence aggregation propensity throughout the entire huntingtin protein. Current therapeutic approaches focus on targeting the N17 domain and understanding how specific residues control mutant huntingtin behavior, providing multiple potential intervention points. The involvement of post-translational modification enzymes like ZDHHC17 (palmitoylation) and the ubiquitin-proteasome system components (UBE2K, RNF20) among huntingtin's interactors suggests that modulating these pathways could offer additional therapeutic strategies. ## Research Directions Critical knowledge gaps remain regarding the precise molecular mechanisms by which the Q23 expansion length drives pathology compared to normal-length or longer expansions. Further investigation is needed to determine whether CP-HTT-001 can effectively prevent aggregation in cellular and animal models, and whether targeting residues 1497-1501 can ameliorate downstream pathology despite the proximal exon 1 mutation. Understanding the interplay between the N17 domain, the polyglutamine tract, and C-terminal aggregation hotspots could reveal novel combination therapeutic strategies. Additionally, characterizing how the Q23 variant affects interactions with ZDHHC17, UBAC1, and other binding partners may identify biomarkers for disease progression or new druggable targets. Population-based studies to establish penetrance and phenotypic variability of the Q23 expansion would inform genetic counseling and clinical trial design.